Journal of Biological Chemistry · 2019 · 28 citations · 44 references
Life SciencesMolecular BiologyOncologyCancer GeneticsMolecular OncologyNeoplasiaCancer Cell SignalingEnzyme FunctionE3 Ubiquitin Ligase Substrate RecognitionGlycogen Synthase Kinase 3 RegulationGlycogen Synthase Kinase RegulationProteasomal TurnoverRegulation By E3 Ubiquitin LigasesScf Ubiquitin Ligase ComplexSubstrate Recognition In Ubiquitin PathwaysTumor Suppressor P53
multiprotein E3 ligase complex, targets both WT and tumor-derived mutants of p53 for proteasomal degradation in multiple human cancer cell lines (HCT116 and U2OS). We found that lack of FBW7α stabilizes p53 levels, thereby increasing its half-life. p53 ubiquitylation and subsequent degradation require the F-box and the C-terminal WD40 repeats in FBW7α. The polyubiquitylation of p53 occurred via Lys-48 linkage and involved phosphorylation on p53 at Ser-33 and Ser-37 by glycogen synthase kinase 3β (GSK3β) and DNA-dependent protein kinase (DNA-PK), respectively. These phosphorylation events created a phosphodegron that enhanced p53 binding to FBW7α, allowing for the attachment of polyubiquitin moieties at Lys-132 in p53. FBW7α-dependent p53 polyubiquitylation apparently occurred during and immediately after DNA double-strand breaks induced by either doxorubicin or ionizing radiation. Accordingly, in cells lacking FBW7α, p53 induction was enhanced after DNA damage. Phosphodegron-mediated polyubiquitylation of p53 on Lys-132 had functional consequences, with cells in which FBW7α-mediated p53 degradation was abrogated exhibiting enhancement of their tumorigenic potential. We conclude that p53, which previously has been reported to transactivate FBW7, is also targeted by the same E3 ligase for degradation, suggesting the presence of a regulatory feedback loop that controls p53 levels and functions during DNA damage.
44
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves et al. · Science · 2004 · 4.7K citations
Medicine, Oncology, Pharmacology +15
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Yunje Cho, Svetlana S. Gorina, Philip D. Jeffrey et al. · Science · 1994 · 2.5K citations
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue, Lars Zender, Cornelius Miething et al. · Nature · 2007 · 2.4K citations
Medicine, Cancer Biology, Oncology +16
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Reiko Honda, Hirofumi Tanaka, Hideyo Yasuda · FEBS Letters · 1997 · 1.9K citations
Restoration of p53 function leads to tumour regression in vivo
Andrea Ventura, David G. Kirsch, Margaret E. McLaughlin et al. · Nature · 2007 · 1.8K citations